3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Interventions
Rituximab
6
Lenalidomide
3
Bendamustine Hydrochloride
3
pirtobrutinib
2
Cyclophosphamide
2
venetoclax
1
umbralisib
1
ublituximab
1
tocilizumab
1
obinutuzumab
1
idelalisib
1
glofitamab
1
fludarabine
1
atezolizumab
1
acalabrutinib
1
Vincristine
1
Standard of Care
1
Prednisone
1
Doxorubicin
1
Brentuximab Vedotin
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Non-Hodgkin
×
fludarabine
×
Clear all
NCT04245839
2025-11-05
TRANSCEND FL
Celgene
Phase 2
Active not recruiting
276 enrolled
2 FDA